comparemela.com

Page 5 - Andrew Dauber News Today : Breaking News, Live Updates & Top Stories | Vimarsana

KOL Review of Lumos Pharma s Interim Phase 2 Data Supports Potential for New Oral Therapeutic Paradigm for Moderate Idiopathic PGHD Patients Seite 1

12.12.2022 - AUSTIN, Texas, Dec. 12, 2022 (GLOBE NEWSWIRE) - Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on rare disorders, hosted two key opinion leaders (KOLs) in the field of pediatric endocrinology on December 6th . Seite 1

United statesErick hawkinsFernando cassorlaAndrew dauberLumos pharmaUniversity of chileChildren national hospitalLumos pharma incPediatric growth hormone deficiencyNational hospitalPediatric endocrinology

Lumos Pharma to Host KOL Webinar to Discuss Interim Phase 2

AUSTIN, Texas, Nov. 29, 2022 (GLOBE NEWSWIRE) Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on rare endocrine.

New yorkUnited statesNew enterpriseUniversity of cincinnatiAlbany medical centerRicharde weitzmanFernando cassorlaAndrew dauberLisa millerLumos pharmaChilean academy of medicineUniversity of chileCincinnati centerSociety for pediatric researchEndocrine societyGenomics first for undiagnosed diseases program

Lumos Pharma to Host KOL Webinar to Discuss Interim Phase 2 Data from OraGrowtH Trials in PGHD

29.11.2022 - AUSTIN, Texas, Nov. 29, 2022 (GLOBE NEWSWIRE) - Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on rare endocrine disorders, announced that the Company will host two key opinion leaders in the field of . Seite 1

United statesFernando cassorlaAndrew dauberUniversity of chileChildren national hospitalLumos pharma incPediatric growth hormone deficiencyNational hospitalPediatric endocrinology

vimarsana © 2020. All Rights Reserved.